Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | GMNN | O75496 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL6637655 | 0.88 | MEN1 (0.65) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6635915 | 0.86 | CYP1A2 (0.57) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL5427277 | 0.83 | LMNA (0.57) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL15813909 | 0.83 | LMNA (0.57) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL16915065 | 0.83 | LMNA (0.57) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL12137165 | 0.79 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL3193491 | 0.79 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL21631711 | 0.79 | MEN1 (0.60) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL29137661 | 0.79 | MEN1 (0.60) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL19923321 | 0.78 | LMNA (0.62) | LMNASMN1; SMN2CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | claimed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | claimed |
| CN-113387836-A | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2021-09-14 | — | — | CN | claimed |
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2021-06-24 | — | — | US | claimed |
| EP-3164125-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | Nan Global, LLC (US) | 2017-05-10 | — | — | EP | claimed |
| WO-2016004363-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN Global, LLC (US) | 2016-01-07 | — | — | WO | claimed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | claimed |
| EP-1218001-B1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-12-31 | — | — | EP | claimed |
| US-7303765-B2 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2007-12-04 | — | — | US | claimed |
| CN-1706814-A | Ultrafine-l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-12-14 | — | — | CN | claimed |
| US-20050124558-A1 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2005-06-09 | — | — | US | claimed |
| EP-1218001-A4 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-05-18 | — | — | EP | claimed |
| CN-1399549-A | Ultra-fine L-carnitine, methods of making, compositions containing, and methods of using | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2003-02-26 | — | — | CN | claimed |
| US-20020111383-A1 | Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-08-15 | — | — | US | claimed |
| EP-1218001-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Sigma-Tau Healthscience S.p.A. (IT) | 2002-07-03 | — | — | EP | claimed |
| WO-2001017525-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA-TAU HEALTHSCUIENCE S.P.A (IT) | 2001-03-15 | — | — | WO | claimed |
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GARCÍA SADA, FERNANDO (MX) | 2024-11-14 | — | — | US | disclosed |
| EP-4393486-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2024-07-03 | — | — | EP | disclosed |
| CN-1399549-A | Ultra-fine L-carnitine, methods of making, compositions containing, and methods of using | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2003-02-26 | — | — | CN | disclosed |
| US-20020111383-A1 | Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | LMNA 521/4885SMN1; SMN2 2914/4885CYP1A2 4593/4885 |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | LMNA 521/4885SMN1; SMN2 2914/4885CYP1A2 4593/4885 |
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GPR119, GPR27, PTPN7 | LMNA 3008/4885SMN1; SMN2 3031/4885CYP1A2 4523/4885 |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | LMNA 521/4885SMN1; SMN2 2914/4885CYP1A2 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.